Changing Possibilities in Haemophilia®
Novo Nordisk is committed to Changing Possibilities in Haemophilia®, working towards a future where all people living with haemophilia, with or without inhibitors, have the opportunity to lead the life they desire.
The Changing Possibilities in Haemophilia® programme has three overarching ambitions, to;
- Strengthen understanding of haemophilia in the broader society
- Improve access to diagnosis, care and treatment
- Advance treatment and care through innovation
At the heart of our commitment are 20 years of research into bleeding disorders and our promise to patients and communities; to listen and learn and work with them for improvements in outcomes.
Inspired by the dedication and courage throughout the haemophilia community, we are driven by a passion for making a difference for all people with haemophilia.
What we do
Building on our achievements in treating haemophilia with inhibitors, we aim to be a respected leader in haemophilia. Novo Nordisk has an industry-leading pipeline portfolio, addressing the many faces of haemophilia and with the potential to innovate the treatment options.
We recognise however that medical products are only part of the response to haemophilia and our broader commitment to the haemophilia community is vital to realising our ambitions.
Working with representatives from across the haemophilia community we are continuously strengthening understanding. This has recently resulted in a new initiative launched in 2010. This largest multi-country psychosocial survey conducted to date in haemophilia, HERO (Haemophilia Experiences, Results and Opportunities) will provide new evidence of what it is like to live with haemophilia.
We work to improve access to diagnosis, care and treatment primarily through our commitment to the Novo Nordisk haemophilia Foundation, established in 2005, focusing on capacity building, awareness creation as well as improving diagnosis and registries. The Foundation has an impact around the world supporting healthcare professionals and reaching out to people with haemophilia and allied bleeding disorders, their family members and other community members.
Finally, we collaborate with patient and medical organisations around the world to advance treatment and care through innovation supporting education and advocacy and the development of new thinking. As an example, our Access to Insight programme supports global haemostasis research with grants, scholarships and awards.
Our approach is to work through global, regional and local partnerships and, working together, we will change possibilities in haemophilia.
HERO is an international community inquiry initiated and supported by Novo Nordisk. This initiative will build a solid understanding of life with haemophilia, seen from the perspective of people with haemophilia, their families and their healthcare providers. It is our goal that their voices are heard to bring about action and change.
